天津医药

天津医药 ›› 2019, Vol. 47 ›› Issue (1): 47-50.doi: 10.11958/20181139

• 临床研究 • 上一篇    下一篇

冠脉内注射硝普钠对老年STEMI患者直接PCI 预防无复流现象的疗效评价

孙小强，李姮，何峰△   

  1. 基金项目：天津市慢性病防治科技重大专项项目（17ZXMFSY00200） 作者单位：天津市第四中心医院心内科，天津医科大学第四中心临床学院（邮编300140） 作者简介：孙小强（1982），男，硕士，主治医师，主要从事冠心病介入治疗 △通讯作者 E-mail: 28963196@qq.com
  • 收稿日期:2018-07-27 修回日期:2018-11-15 出版日期:2019-01-15 发布日期:2019-01-15
  • 通讯作者: 孙小强 E-mail:sxqmed@163.com

Curative effect of intracoronary injection of sodium nitroprusside on no-reflow phenomenon in elderly patients with STEMI treated by primary percutaneous coronary intervention

SUN Xiao-qiang, LI Heng, HE Feng△   

  1. Department of Cardiovascular, the Fourth Center Clinical College of Tianjin Medical University, Tianjin Fourth Central Hospital, Tianjin 300140, China △Corresponding Author E-mail: 28963196@qq.com
  • Received:2018-07-27 Revised:2018-11-15 Published:2019-01-15 Online:2019-01-15
  • Contact: Xiao-Qiang SUN E-mail:sxqmed@163.com

PDF (PC)

3801

摘要： 目的 探讨冠状动脉内预防性注射硝普钠对老年ST段抬高型心肌梗死（STEMI）患者直接经皮冠状动脉 介入治疗（pPCI）预防无复流的安全性与疗效。方法 将185例行pPCI的STEMI老年患者采用完全随机化方法分为 对照组（93例）与硝普钠组（92例）。硝普钠组开通冠脉后立即注射硝普钠200 μg，对照组注射等量的生理盐水。比 较2组患者术中无复流发生情况及术后肌钙蛋白T（cTnT）、估测射血分数（EF），住院期间及随访1年主要不良心血管 事件（MACE）发生率，并分析无复流发生危险因素。结果 硝普钠组左心室射血分数（LVEF）及估测EF明显高于对 照组，而cTnT及C-反应蛋白（CRP）明显低于对照组（P＜0.05）；硝普钠组无复流发生比例、支架植入数目明显低于对 照组（P＜0.05），2组间梗死相关动脉分布、TIMI血流分级冠脉Gensini评分及SYNTAX评分差异均无统计学意义；住 院期间2组MACE事件发生率差异无统计学意义，随访1年期间硝普钠组MACE事件发生率明显少于对照组（P＜ 0.05）。Logistic回归分析显示，未应用硝普钠、糖尿病、高SYNTAX评分为无复流发生的独立危险因素。结论 硝普 钠可明显减少接受pPCI治疗的老年STEMI患者的无复流发生率，减少1年MACE事件发生率，且具有良好的安全性。

关键词: 心肌梗死, 血管成形术, 经腔, 经皮冠状动脉, 硝普钠, 无复流现象, ST段抬高型心肌梗死, 直接经皮冠状 动脉介入治疗

Abstract: Objective To investigate the safety and efficacy of prophylactic injection of sodium nitroprusside in primary percutaneous coronary intervention (pPCI) without reflow in elderly patients with ST segment elevation myocardial infarction (STEMI). Methods A total of 185 elderly patients with STEMI were divided into sodium nitroprusside group (n= 92) and control group (n=93) with completely randomized design. All patients were treated with pPCI. Sodium nitroprusside group received sodium nitroprusside 200 μg immediately after opening coronary artery. Control group received equal amount of physiological saline. The incidence of no-reflow, the levels of troponin T (cTnT) and ejection fraction (EF), the incidence of major adverse cardiovascular events (MACE) during hospitalization and 1 year follow-up were compared between two groups, and the risk factors of no-reflow were analyzed. Results In nitroprusside group, the incidence of no flow and cTnT, CRP, and the number of stent were significantly lower and LVEF, EF were significantly higher than those in control group (P＜0.05). There were no significant differences in HbA1c, infarct related artery (IRA), TIMI grade, Gensini score, SYNTAX score and incidence of MACE during hospitalization between two groups (P＞0.05). In nitroprusside group, the incidence of MACE in 1-year follow-up was significantly lower than that in control group (P＜0.05). Logistic regression analysis showed that without injection of nitroprusside, diabetes and the high SYNTAX scores were independent risk factors for no reflow. Conclusion The application of sodium nitroprusside can significantly reduce the incidence of no flow and MACE in 1-year follow up in elderly patients with STEMI treated with pPCI，and which has good safety.

Key words: myocardial infarction, angioplasty, transluminal, percutaneous coronary, nitroprusside, no-reflow phenomenon, ST segment elevation myocardial infarction, primary percutaneous coronary intervention